ESMO 2021 Lung Cancer – Oliver Gautschi
Oliver Gautschi highlights the most relevant findings presented at ESMO 2021 in terms of lung cancer, innovative treatment approaches currently tested for use in patients with unresectable malignant pleural mesothelioma, immunotherapeutic approaches in the setting of thymoma and thymic carcinoma and summarizes potential strategies for the management of RET-positive NSCLC.
Here is the full ESMO 2021 Lung Cancer report.
More posts
ATALANTE-1: anti-cancer vaccination after IO failure
ATALANTE-1: anti-cancer vaccination after IO failure OSE-2101 is an anti-cancer
Gradual progress in the management of mesothelioma and thymoma
Gradual progress in the management of mesothelioma and thymoma Oliver Gautschi,
Malignant pleural mesothelioma: immunotherapy-based approaches in all treatment lines
Malignant pleural mesothelioma: immunotherapy-based approaches in all treatment lin
Small-cell lung cancer: on the road to improved efficacy and tolerability
Small-cell lung cancer: on the road to improved efficacy and tolerability ATLAN
Immunotherapy: boosting efficacy and overcoming resistance
Immunotherapy: boosting efficacy and overcoming resistance POSEIDON: durvalumab
Innovative and established agents across a range of targets
Innovative and established agents across a range of targets Anti-HER2 treatment
